Loading stock data…
Sutro Biopharma (STRO)
$33.47+2.95 (+9.67%)
Market OpenUpdated 3:10 PM EDT
Sutro Biopharma, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sutro Biopharma, Inc. in the Healthcare sector is trading at $33.47 with a market capitalization of $478M. Wall Street consensus targets $48.31 (13 analysts), implying a +44.3% move over the next 12 months. The stock is currently 24% below its 52-week high of $43.85, remaining 79.3% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +44.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $14.52M↑ | $11.65M↑ | $9.69M↓ | $63.74M↑ | $17.40M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$29.61M↑ | -$33.66M↑ | -$38.90M↓ | $15.08M↑ | -$47.47M |
| Net Income | -$38.48M↑ | -$46.76M↑ | -$56.86M↓ | -$11.50M↑ | -$75.97M |
Peer Comparison
JNJUNHPFE
Fundamentals
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conju...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$478.06M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
229.64%
Volume
Today's trading volume
256,849
Recent News
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials.
Barclays initiates oncology-focused biotechs with positive outlook
Investing.com -- Barclays initiated coverage of four small- and mid-cap biotechnology companies in a note to clients on Thursday, calling the stocks differentiated platform plays with the potential to deliver meaningful advances across tumor types and treatment modalities.
News Flash: Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Forecasts
Celebrations may be in order for Sutro Biopharma, Inc. ( NASDAQ:STRO ) shareholders, with the analysts delivering a...
US$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These Results
Sutro Biopharma, Inc. ( NASDAQ:STRO ) just released its latest first-quarter results and things are looking bullish...
MannKind (MNKD) Reports Q1 Loss, Misses Revenue Estimates
MannKind (MNKD) delivered earnings and revenue surprises of -150.00% and -13.05%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?